Risk factors for sudden cardiac death in hypertrophic cardiomyopathy by Efthimiadis, Georgios K. et al.
IntroductIon
Hypertrophic cardiomyopathy (HCM) is the most 
common cause of sudden death (SD) in young people, 
including trained athletes1. Since the major character-
istic of HCM is its clinical heterogeneity, risk factors 
for SD may differ among countries, even among re-
gions of a single country. Aim of our study was the 
identification of the clinical markers for SD in a co-
hort of HCM patients coming from Northern Greece.
Methods
Study population
Two hundred and ninety five consecutive patients with 
documented HCM have been assessed from February 
1992 to December 2007 in AHEPA Hospital, Thessa-
loniki, Greece, and are currently followed-up in our 
Institution. The diagnosis of HCM was based on the 
demonstration by two dimensional echocardiography 
of left ventricular maximum wall thickness (LVMWT) 
greater or equal to 15 mm, in the absence of any other 
cause capable of producing such hypertrophy2,3. HCM 
was also considered present in patients with LVMWT 
13 or 14 mm in the presence of a positive family his-
tory for HCM and/or electrocardiographic (ECG) 
changes compatible with the disease. 
In this study we included patients who had under-
taken all non invasive tests for risk stratification; clini-
cal evaluation; 12-lead ECG; transthoracic echocar-
diography; 24-h ambulatory ECG monitoring; and 
symptom-limited upright exercise test. Patients with 
documented sustained ventricular tachycardia (VT) 
or out-of-hospital cardiac arrest and those who were 
on amiodarone at first evaluation were excluded.. The 
presence or absence of any other medications was not 
used as a selection criterion. The final study cohort 
comprised 166 patients from the whole HCM regis-
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try meeting the aforementioned criteria. Six non in-
vasive-clinical features were tested as potential risk 
factors for SD: 1) Syncope. A history of syncope was 
defined as one or more episodes of unexplained loss 
of consciousness preceding patient’s first visit to our 
Hospital. 2) Premature sudden death. A family history 
of premature SD was defined as SD in one or more 
first-degree relatives <50 years old. 3) Non-sustained 
ventricular tachycardia (NSVT). NSVT was defined 
as a run of three or more consecutive ventricular 
beats at a rate of ≥120 beats/min, lasting <30 s. 4) Ab-
normal blood pressure response (ABPR). An ABPR 
was defined as a failure of systolic blood pressure to 
rise more than 20 mmHg, or a fall of systolic blood 
pressure >10 mm Hg, during exercise. 5) Excessive 
hypertrophy. Excessive hypertrophy was defined if 
LVMWT was ≥3 cm in any myocardial segment. 6) 
LV outflow tract obstruction (LVOTO) with a peak 
gradient ≥30 mm Hg.
 Commencement of patients’ follow-up was de-
fined as the time the initial diagnosis was made even 
if the diagnosis preceded baseline patient evalua-
tion in our clinic. The patients were followed every 
12 months, unless an important clinical event-reason 
urged for more frequent evaluation. 
The endpoint of the study was defined as SD, car-
diac arrest, documented sustained VT, or Implantable 
Cardioverter Defibrillator (ICD)-discharge. All pa-
tients gave written informed consent and the protocol 
of the study was reviewed and approved by the insti-
tutional ethics committee.
Echocardiography
Echocardiographic studies were performed using com-
mercially available equipments. Echocardiographic 
examination included M-mode, two-dimensional, 
pulsed- and continuous-wave Doppler echocardiogra-
phy, as well as Tissue Doppler Imaging. Segmental 
LV hypertrophy was measured by two-dimensional 
echocardiography in the parasternal short axis plane 
at the level of mitral valve and the papillary muscles 
according to previous described methods.3 Standard 
M-mode measurements were made according to the 
recommendations of the American Society of Echocar-
diography4. Basal subaortic gradient was determined 
using continuous wave Doppler echocardiography and 
the modified Bernouilli equation from the apical three 
and five chambers view5. LVOTO was considered to 
be present when the peak instantaneous outflow gradi-
ent was estimated to be at least 30 mm Hg with the use 
of continuous-wave Doppler echocardiography under 
resting conditions5.
Stress test
Patients underwent symptom-limited upright treadmill 
exercise test using the Bruce protocol. Blood pressure 
was estimated using a mercury sphygmomanometer 
and auscultation of the Korotkoff sounds over the bra-
chial artery at rest, every minute during exercise and 
for the first 3 min of recovery.
Holter monitoring
All patients underwent 24-h ambulatory electrocardi-
ography while performing ordinary daily activities.
stAtIstIcAl AnAlysIs
Continuous data are expressed as mean±SD or median 
(25th to 75th percentile) based on whether they have 
a normal distribution or not. Categorical data are pre-
sented as absolute values and percentages. 
 Survival was plotted according to the Kaplan-
Meier method. Potential independent predictors of 
outcome were identified by univariate analyses. All 
univariate predictors were then entered in a stepwise 
manner into a multivariable Cox proportional-hazards 
regression model, with entry and retention set at a sig-
nificance level of <0.05. 14.0 (SPSS Inc., Chicago, Il-
linois) was used for all analyses.
results
The mean age at diagnosis for the cohort of 166 pa-
tients (67.4% male) was 47.9 ± 16.3 years (range 5 
to 81 years), and the mean age at first evaluation was 
51.8 ± 15.6 years (range 16 to 81 years.) The median 
follow-up duration was 32.4 months (range 1 to 209 
months). In 102 patients (61.4%) the diagnosis was 
made in other hospitals or by out hospital cardiolo-
gists. These patients were then referred to our Institu-
tion for further evaluation. Fifty one patients (30.7%) 
had a family history of HCM, 21 patients (12.6%) 
had paroxysmal or permanent atrial fibrillation, 119 
patients (71.6%) were on cardioactive medication, 
19 patients (11.4%) were NYHA class III or IV the 
day of first evaluation. The prevalence of risk factors 
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was: syncope in 14.4% of patients; family history of 
premature SD in 9.6%; NSVT in 16.8%; ABPR in 
26.5%; LVMWT ≥3 cm in 9%; and LVOTO with a 
peak gradient ≥30 mm Hg in 30.1% of patients. The 
above data are outlined in Table 1.
During the follow up period 13 patients reached 
study’s end point. More specifically, 1 died suddenly, 
2 had resuscitated cardiac arrest, 5 experienced ven-
tricular tachycardia/ventricular fibrillation (VT/VF) 
and 5 patients experienced an appropriate ICD-inter-
vention. The cumulative event-free survival rate was 
92.2% in our study cohort. Using univariate analysis, 
we showed that patients having experienced syncope 
or presenting with a LVMWT ≥3cm in echocardiogra-
phy or manifestating NSVT in Holter ECG were more 
sensitive to SD emergence since they had a 13.07 
(95%CI: 4.00-46.95, p < 0.0001), a 10.07 (95%CI: 
2.92-34.79, p = 0.003) and a 3.53 (95%CI: 1.06-11.75, 
p = 0.03) greater relative risk respectively (Table 2). 
In a stepwise multivariable regression model includ-
ing the traditional referred risk factors (syncope, fam-
ily history of premature SD, LVMWT ≥3 cm, ABPR 
on exercise, NSVT in 24-h Holter monitoring), and 
the presence of resting LVOTO, the only independent 
prognostic indicators were a LVMWT ≥3 cm and the 
presence of syncope (Table 3).
dIscussIon
In our cohort of HCM patients a previous unexplained 
syncope along with a LVMWT ≥3 cm were the most 
powerful predictors of SD. Risk stratification in HCM 
patents without a history of sustained VT or docu-
mented cardiac arrest is a big clinical challenge and 
sometimes very difficult. 
According to previous studies, 5 non invasive 
clinical markers were thought to be potential risk fac-
tors for SD: Syncope, Family History of SD, NSVT, 
ABPR during exercise and LVMWT in any myocar-
table 1. Demographic and clinical characteristics of 166 patients with HCM.
Variable overall Population (n = 166)
demographics
Age at initial evaluation, y
Age at diagnosis, y
Follow up, months
Male gender 
Referrals
Family history of HCM
51.8±15.6
47.9±16.3 
32.4 (1-209)
112 (67.4%)
102 (61.4%)
51 (30.7%)
nyhA class  III/ IV 19 (11.4%)
AF 21 (12.6%)
risk factors
Syncope
Family history of SD
NSVT
ABPR
LVMWT ≥3 cm
LVOTO
24 (14.4%)
16 (9.6%)
28 (16.8%)
44 (26.5%)
15 (9%)
50 (30.1%)
Medications 119 (71.6%)
endpoint 13 (7.8%)
Values are expressed as mean ± SD, median (range) or number (percentage). HCM = hy-
pertrophic cardiomyopathy, NYHA = New York Heart Association, AF = atrial fibrillation,  
SD = sudden death, NSVT = nonsustained ventricular tachycardia, ABPR = abnormal blood 
pressure response, LVMWT = left ventricular maximum wall thickness, LVOTO = left ven-
tricular outflow tract obstruction
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dial segment of ≥3 cm6-10. Previous studies have also 
suggested that HCM patients with LVOTO carry an 
increased risk of cardiovascular death11,12. However, 
the prognostic value of LVOTO in estimation of SD 
risk, has been a subject of intense controversy leading 
to expertise discrepancy13,14.
In our study we tested the aforementioned 5 non 
invasive clinical markers along with the presence of 
LVOTO, as potential risk factors for SD. Among these 
clinical markers, unexplained syncope and LVMWT 
≥3 cm were found as the only independent predictors 
for SD in patients with HCM. Regarding the role of 
LVOTO on the incidence of SD, our results are com-
parable with the results of previous studies.13,14 On the 
contrary, no prognostic value was recognised for the 
rest 3 factors. The recorded disparity regarding the 
comparison of our results with preceding studies6-10 
may be due to the unique clinical and genetic hetero-
geneity of the disease, along with the low mortality 
rates for SD also reported by our study. Both of the 
fore mentioned factors do not allow addressing clearly 
the sensitivity of the potential risk factors, a combined 
sensitivity not exceeding 20%. Furthermore, influence 
of possible confounding factors, such as age and treat-
ment, is an issue to be kept in mind since their poten-
tial impact on SD prevalence is important.
The early and valid recognition of HCM patients 
being prone to SD, is of major importance since im-
plantation of ICD may be in fact life saving. Unfor-
tunately, the existing clinical indices fail to lead to an 
ultimate patient selection, i.e. to select patients being 
most appropriate for CD implantation. Our study re-
sults endorse only 2 of the 5 potential clinical risk fac-
tors for SD in HCM, previously introduced, address-
ing for one more time the need to clarify the existing 
risk factors or even recognize new more sensitive and 
accurate. 
SD among HC patients is mainly connected to the 
occurrence of VT/VF15. There are many studies sug-
gesting that the extent of myocardial disarray-fibrosis, 
predisposing to re-entry phenomena as part of general 
arrhythmogenic tendency, constitutes the main stimu-
table 2. Univariate analysis between risk factors and sudden death/cardiac arrest/ventricular tachycardia/ventricular  
fibrillation/implantable cardioverter defibrillator-discharge in 166 Patients with HCM.
Variable rr (95%cI) univariate p
FHSCD 1.81 (0.36-8.98) 0.47
Syncope 13.70 (4.00-46.95) <0.0001
LVMWT ≥3 cm 10.07 (2.92-34.79) 0.0003
NSVT 3.53 (1.06-11,75) 0.03
ABPR 1.26 (0.37-4.30) 0.71
LVOTO≥30 mmHg 1.03 (0.30-3.53) 0.95
ABPR = abnormal blood pressure response, FHSCD= Family History of Sudden Cardiac Death, LVMWT = left 
ventricular maximum wall thickness, NSVT = nonsustained ventricular tachycardia. LVOTO,= left ventricular out-
flow tract obstruction
table. Multivariate analysis between risk factors and sudden death/cardiac arrest/ventricular tachycardia/ventricular  
fibrillation/implantable cardioverter defibrillator-discharge in 166 Patients with HCM
Variable rr ( 95%cI) univariate p
Syncope 10.40 (2.67-40.56) 0.0007
LVMWT ≥3 cm 7.46 (1.83-30.50) 0.005
NSVT 1.41 (0.33-6.09) 0.64
LVMWT = left ventricular maximum wall thickness, NSVT = nonsustained ventricular tachycardia.
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lus for VT/VF incidence and the appearance of SD 
consecutively16. Maybe, the extent of myocardial dis-
array-fibrosis in hypertrophic myocardium as this is 
assessed by newer techniques such as Delayed Hyper 
Enhancement Magnetic Resonance Imaging could be 
a creditable risk factor for SD, something that should 
be examined in future prospective studies17,18.
ΠΕΡΙΛΗΨΗ: Σκοπός της παρούσας μελέτης είναι η αξιολόγηση έξι μη επεμβατικών κλινικών δεικτών ως παραγόντων 
κινδύνου για αιφνίδιο θάνατο σε ασθενείς με υπερτροφική μυοκαρδιοπάθεια. Προηγηθείσα συγκοπή, οικογενειακό ιστορικό 
αιφνιδίου θανάτου, μη εμμένουσα κοιλιακή ταχυκαρδία, μη φυσιολογική απάντηση της αρτηριακής πίεσης κατά τη διάρκεια 
άσκησης, υπερτροφία που υπερβαίνει τα 3 cm, και απόφραξη του χώρου εκροής της αριστεράς κοιλίας με κλίση πιέσεως 
≥30mm Hg ήταν οι παράγοντες που αξιολογήθηκαν σε μια κοόρτη 166 ασθενών (112 άρρενες, 51.8 ± 15.6 ετών), οι οποίοι 
παρακολουθήθηκαν για ένα διάστημα 32,4 μηνών (από 1 έως και 290 μήνες). Κατά τη διάρκεια της παρακολούθησης τα 
τελικά σημεία της μελέτης παρατηρήθηκαν σε 13 ασθενείς: αιφνίδιος θάνατος, καρδιακή ανακοπή, διαπιστωμένη εμμένουσα 
κοιλιακή ταχυκαρδία και/ή εκφόρτιση εμφυτευμένου απινιδωτή. Οι ασθενείς με ιστορικό συγκοπικού επεισοδίου ή αυτοί που 
παρουσίασαν υπερτροφία οποιουδήποτε καρδιακού τοιχώματος ≥3 cm στο υπέρηχο-καρδιογράφημα ήταν πιο ευαίσθητοι 
στην εμφάνιση αιφνιδίου θανάτου από τη στιγμή που παρουσίασαν 13,07 (95%CI: 4,00-46,95, p < 0,0001) και 10,07 (95%CI: 
2,92-34,79, p = 0,003) μεγαλύτερο κίνδυνο αντίστοιχα. Στην κοόρτη των ασθενών μας μόνο 2 από τους 6 «αναγνωρισμένους» 
πιθανούς παράγοντες για αιφνίδιο θάνατο βρέθηκαν ευαίσθητοι στην πρόβλεψη μελλοντικών συμβαμάτων, ένα αποτέλεσμα 
που προκαλεί σκεπτικισμό σχετικά με την εγκυρότητα των κριτηρίων που χρησιμοποιούνται για εμφύτευση απινιδωτή προς 
αποτροπή αιφνιδίου θανάτου στην υπερτροφική μυοκαρδιοπάθεια.
Λέξεις Kλειδιά: Παράγοντες κινδύνου, Αιφνίδιος θάνατος, Υπερτροφική μυοκαρδιοπάθεια.
Παράγοντες κινδύνου για αιφνίδιο θάνατο σε ασθενείς  
με υπερτροφική μυοκαρδιοπάθεια.
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